<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pediatr Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">J Pediatr Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">1334</journal-id><journal-id journal-id-type="pmc-domain">jppt</journal-id><journal-id journal-id-type="publisher-id">jppt</journal-id><journal-title-group><journal-title>The Journal of Pediatric Pharmacology and Therapeutics : JPPT</journal-title></journal-title-group><issn pub-type="ppub">1551-6776</issn><issn pub-type="epub">2331-348X</issn><publisher><publisher-name>Pediatric Pharmacology Advocacy Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11001209</article-id><article-id pub-id-type="pmcid-ver">PMC11001209.1</article-id><article-id pub-id-type="pmcaid">11001209</article-id><article-id pub-id-type="pmcaiid">11001209</article-id><article-id pub-id-type="pmid">38596427</article-id><article-id pub-id-type="doi">10.5863/1551-6776-29.2.180</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Ceftriaxone Pharmacokinetics and Pharmacodynamic Target Attainment for Three Pediatric Patients Receiving Continuous Kidney Replacement Therapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hambrick</surname><given-names initials="HR">H. Rhodes</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cervantes</surname><given-names initials="F">Francisco</given-names></name><degrees>BS</degrees><xref rid="aff3" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="M">Min</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="P">Peter</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff"/><xref rid="aff5" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arbough</surname><given-names initials="T">Trent</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vinks</surname><given-names initials="AA">Alexander A.</given-names></name><degrees>PharmD, PhD</degrees><xref rid="aff2" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mizuno</surname><given-names initials="T">Tomoyuki</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goldstein</surname><given-names initials="SL">Stuart L.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/><xref rid="aff4" ref-type="aff"/><xref rid="aff7" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaplan</surname><given-names initials="J">Jennifer</given-names></name><degrees>MD, MS</degrees><xref rid="aff4" ref-type="aff"/><xref rid="aff8" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Girdwood,</surname><given-names initials="ST">Sonya Tang</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4" ref-type="aff"/><xref rid="aff9" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Division of Nephrology and Hypertension (HRH, SLG), Cincinnati Children&#8217;s Hospital Medical Center, Cincinnati, OH;</aff><aff id="aff2">Division of Clinical Pharmacology (HRH, MD, AAV, TM, STG), Cincinnati Children&#8217;s Hospital Medical Center, Cincinnati, OH;</aff><aff id="aff3">Department of Medical Education (FC), University of Cincinnati College of Medicine, Cincinnati, OH;</aff><aff id="aff4">Department of Pediatrics (MD, PT, AAV, TM, SLG, JK, STG), University of Cincinnati College of Medicine, Cincinnati, OH;</aff><aff id="aff5">Division of Pathology and Laboratory Medicine (PT), Cincinnati Children&#8217;s Hospital Medical Center, Cincinnati, OH; </aff><aff id="aff6">Department of Anesthesiology (TA), University of Kentucky College of Medicine, Lexington, KY; </aff><aff id="aff7">Center for Acute Care Nephrology (SLG), Cincinnati Children&#8217;s Hospital Medical Center, Cincinnati, OH; </aff><aff id="aff8">Division of Critical Care Medicine (JK), Cincinnati Children&#8217;s Hospital Medical Center, Cincinnati, OH; </aff><aff id="aff9">Division of Hospital Medicine (STG), Cincinnati Children&#8217;s Hospital Medical Center, Cincinnati, OH.</aff><author-notes><corresp id="cor1"><bold>Correspondence.</bold> H. Rhodes Hambrick, MD; <email>horace.hambrick@cchmc.org</email></corresp><fn fn-type="COI-statement"><p><bold>Disclosure.</bold> The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. The authors had full access to all patient information in this report and take responsibility for the integrity and accuracy of the report.</p></fn></author-notes><pub-date pub-type="ppub" iso-8601-date="2024-04-01"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-04-08"><day>08</day><month>4</month><year>2024</year></pub-date><volume>29</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">459620</issue-id><fpage>180</fpage><lpage>187</lpage><history><date date-type="received"><day>26</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>09</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-10 17:25:13.023"><day>10</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement><bold>Copyright.</bold> Pediatric Pharmacy Association. All rights reserved. For permissions, email: <email>membership@pediatricpharmacy.org</email></copyright-statement><copyright-year>2024</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="i2331-348X-29-2-180.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="i2331-348X-29-2-180.pdf"/><abstract><p>Ceftriaxone is used commonly for sepsis, including in children requiring continuous kidney replacement therapy (CKRT). No reports exist of pharmacokinetic (PK) parameters for children receiving ceftriaxone on CKRT. We enrolled children admitted to our pediatric intensive care unit (PICU) who received CKRT for &gt;24 hours and received &gt;1 dose of ceftriaxone while on and off CKRT. We measured free ceftriaxone &#173;concentrations from residual blood samples then used Bayesian estimation with PK modeling software to generate concentration-time profiles and determine PK parameters and the percentage of time free ceftriaxone concentrations were above 1&#215; or 4&#215; MIC (% <italic toggle="yes">f</italic>T &gt;MIC). Three patients aged 2 to 17 years were included; all were anuric at CKRT initiation and received 50 mg/kg (max 2000 mg) ceftriaxone every 12 to 24 hours. Total ceftriaxone clearance (CL) was 0.50 to 3.67 L/hr while receiving CKRT and 0.29 to 2.71 L/hr while off, indicating CKRT provided 25% to 42% of total ceftriaxone CL. All achieved 100% <italic toggle="yes">f</italic>T &gt;1&#215; and 4&#215; MIC using an estimated MIC (1 mg/L) for patients 1 to 2 (no culture data) and a measured MIC (0.016 mg/L) for patient 3. Therefore, CKRT contributed significantly to total ceftriaxone clearance in 3 children though the dosing strategies used in each patient attained PD targets.</p></abstract><kwd-group><kwd>acute kidney injury</kwd><kwd>ceftriaxone</kwd><kwd>continuous renal replacement therapy</kwd><kwd>extracorporeal clearance</kwd></kwd-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>